PCRX - パシラ・ファ―マシュ―ティカルズ (Pacira Pharmaceuticals Inc.) パシラ・ファ―マシュ―ティカルズ

 PCRXのチャート


 PCRXの企業情報

symbol PCRx
会社名 Pacira Pharmaceuticals Inc. (パシラ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 パキラ・ファーマシューティカルズ(Pacira Pharmaceuticals Inc.)は持株会社である。同社は、主に病院と外来手術センターで使用するために、DepoFoam延長放出ドラッグデリバリー技術に基づいて医薬品の開発・製造・商業化に焦点を当てた製薬会社である。主な製品候補EXPOPEL(ブピバカイン・リポソーム注射可能懸濁液)は、DepoFoamにカプセル化されたアミド型局所麻酔薬ブピバカインで構成され、手術部位への単回用量浸潤が示されて術後鎮痛を生じる。EXPOPELの他、DepoFoamは、他の食品医薬品局で承認された商業用製品DepoCyt(e)の基礎でもあり、商業パートナー及び製品候補向けにDepoCyt(e)を生産する。他の製品候補には、DepoMeloxicam(DepoMLX)およびDepoTranexamic Acid(DepoTXA)が含まれる。DepoCyt(e)はリンパ腫性髄膜炎の髄腔内治療に使用される。   パシラ・ファ―マシュ―ティカルズは、米国の持株会社。救急治療者や患者のニ―ズを満たす新薬の臨床治療・商業開発に焦点を当てる。主力製品は、局所鎮痛剤「EXPAREL」、リンパ腫性髄膜炎の治療のためDEPOFOAM技術を利用した化学療法剤とシタラビンの徐放性リポソ―ム製剤「DepoCyt(e)」などがある。   
本社所在地 5 Sylvan Way Suite 300 Parsippany NJ 07054 USA
代表者氏名 David M. Stack David M. Stack
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 973-254-3560
設立年月日 39052
市場名 NASDAQ National Market System
ipoyear 2011年
従業員数 489人
url www.pacira.com
nasdaq_url https://www.nasdaq.com/symbol/pcrx
adr_tso
EBITDA EBITDA(百万ドル) 17.79000
終値(lastsale) 45.15
時価総額(marketcap) 1849362782.4
時価総額 時価総額(百万ドル) 1925.14
売上高 売上高(百万ドル) 305.12700
企業価値(EV) 企業価値(EV)(百万ドル) 1837.407
当期純利益 当期純利益(百万ドル) -11.11800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Pacira Pharmaceuticals Inc revenues increased 13% to $158.7M. Net loss decreased 80% to $8.1M. Revenues reflect Net product sales increase of 12% to $155M Collaborative licensing and milestone re increase from $336K to $3M. Lower net loss reflects Research and development - Balancing val decrease of 27% to $25M (expense) Product discontinuation decrease of 94% to $252K (expense).

 PCRXのテクニカル分析


 PCRXのニュース

   Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/04/08 01:05:01 Investing.com
Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals
   Jefferies Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/03/19 12:25:58 Investing.com
Jefferies Stick to Their Buy Rating for Pacira Pharmaceuticals
   Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals By Investing.com  2021/03/02 14:48:26 Investing.com
Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals
   Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/19 12:15:33 Investing.com
Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals
   RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/13 01:59:08 Investing.com
RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals
   Jefferies Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/03/19 12:25:58 Investing.com
Jefferies Stick to Their Buy Rating for Pacira Pharmaceuticals
   Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals By Investing.com  2021/03/02 14:48:26 Investing.com
Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals
   Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/19 12:15:33 Investing.com
Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals
   RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/13 01:59:08 Investing.com
RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals
   Needham Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/08 10:25:25 Investing.com
Needham Stick to Their Buy Rating for Pacira Pharmaceuticals
   Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals By Investing.com  2021/03/02 14:48:26 Investing.com
Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals
   Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/19 12:15:33 Investing.com
Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals
   RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/13 01:59:08 Investing.com
RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals
   Needham Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com  2021/01/08 10:25:25 Investing.com
Needham Stick to Their Buy Rating for Pacira Pharmaceuticals
   RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals  2020/12/14 01:45:34 Investing.com
RBC Capital Stick to Their Buy Rating for Pacira Pharmaceuticals

 関連キーワード  (医薬品 米国株 パシラ・ファ―マシュ―ティカルズ PCRX Pacira Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)